LifeStance Health Group (NASDAQ:LFST) Upgraded at The Goldman Sachs Group

LifeStance Health Group (NASDAQ:LFST) was upgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a report issued on Monday, MarketBeat reports. The brokerage presently has a $10.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 33.69% from the company’s previous close.

Separately, Barclays upped their price target on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.70.

LifeStance Health Group Stock Down 3.5 %

LFST opened at $7.48 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -28.77 and a beta of 1.28. LifeStance Health Group has a one year low of $4.64 and a one year high of $9.20. The business’s fifty day moving average is $7.20 and its two-hundred day moving average is $6.36.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.05. The company had revenue of $312.70 million during the quarter, compared to the consensus estimate of $302.25 million. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. LifeStance Health Group’s revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.17) earnings per share. Analysts anticipate that LifeStance Health Group will post -0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Robert Bessler sold 75,000 shares of LifeStance Health Group stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total transaction of $565,500.00. Following the sale, the director now directly owns 1,424,447 shares in the company, valued at $10,740,330.38. The trade was a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is owned by insiders.

Hedge Funds Weigh In On LifeStance Health Group

Several large investors have recently bought and sold shares of the stock. Townsquare Capital LLC bought a new position in shares of LifeStance Health Group during the 3rd quarter valued at about $73,000. Park Edge Advisors LLC acquired a new stake in LifeStance Health Group during the third quarter valued at approximately $73,000. CIBC Asset Management Inc bought a new stake in LifeStance Health Group during the second quarter worth approximately $53,000. Algert Global LLC acquired a new position in LifeStance Health Group in the second quarter worth approximately $57,000. Finally, Victory Capital Management Inc. increased its holdings in shares of LifeStance Health Group by 27.0% in the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after buying an additional 3,063 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.